Search results
Dow Jones Darling Merck Pops As Cancer 'Star' Drives Quarterly Beat
Investor's Business Daily· 7 days agoMerck's bread-and-butter cancer drug grew by double digits again in the first quarter.
Healthcare and drugmaker groups seek to revive challenge to US drug-pricing law
Reuters· 14 hours agoHealthcare and drug industry groups on Wednesday urged a U.S. appeals court to revive their...
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Benzinga via Yahoo Finance· 7 days agoOn Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8...
Is Merck Stock Fully Valued At $130?
Forbes· 1 day agoMerck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates. The growth was primarily driven by higher sales...
20 Fastest Growing Health Tech Companies in the World
Insider Monkey via Yahoo Finance· 7 days agoIn this article, we will be taking a look at the 20 fastest growing health tech companies in the...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 7 days agoIn Diabetes, Januvia/Janumet (diabetes) franchise sales declined 21% year over year to $670 million....
May 1, 2024, Letters to the Editor
The Record-Courier· 1 day agoZephyr Cove Resort previously leased from the Forest Service about a half mile of lakefront. Despite public objections, the Forest Service has now agreed...
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $143.00
ETF DAILY NEWS· 3 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) had its target price boosted by Truist Financial from $142.00 to $143.00 in a research report released on Friday, Benzinga reports. Truist Financial ...